Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals said Monday that an attitudes and experiences survey in connection with a schizophrenia trial showed patient and health care professional satisfaction with TEV-'749 or olanzapine as a once-monthly subcutaneous long-acting injectable.
The company said over 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about the investigational treatment, which was evaluated in the phase 3 subcutaneous olanzapine extended-release injection study.
The company also said that new data from Uzedy assessed predictors of response in schizophrenia, with efficacy seen across patient demographic and clinical characteristics in the phase 3 trial.
Uzedy received approval in the US for the treatment of schizophrenia in adults in 2023, according to the company.
Shares of Teva Pharmaceutical Industries were up 2.6% in recent trading.
Price: 15.48, Change: +0.40, Percent Change: +2.63
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。